Treat the first patient with GPH101
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 17 Nov 2021
- Due
- 30 Jun 2022
- Delivered
- August 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company expects to treat the first patient with GPH101 in the first half of 2022”
What we found
Evidence strength A What the grades mean
The company failed to treat the first patient with GPH101 (nula-cel) by the first half of 2022, ultimately dosing the first patient in August 2022.
-
A LENZ Therapeutics, Inc. 10-Q filed 2022-08-11
“treatment of the first patient in our Phase 1/2 clinical trial of nula-cel was delayed due to screen failure as a result of a prospective participant becoming infected with COVID-19.” ✓ confirmed on the page
-
A LENZ Therapeutics, Inc. 10-Q filed 2022-11-09
“Our Phase 1/2 CEDAR clinical trial of nula-cel is underway, with the first patient dosed with nula-cel in August 2022” ✓ confirmed on the page
Market reaction: the shares moved +10.1% against the S&P 500 over the three sessions around the disclosure (10 Aug 2022 to 15 Aug 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Treat
- Deliverable
- First patient treatment with GPH101
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LENZ-003342 · Corrections policy